We’re tackling the world’s toughest health challenges
Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the medicines of tomorrow. Healthcare areas include: Oncology, Immunology, Neuroscience and Cardiopulmonary.
Johnson & Johnson MedTech innovates at the intersection of biology and technology. With a focus on treating with pinpoint precision in the hardest-to-reach parts of the body, restoring anatomy and reimagining healing, our portfolio of smarter, less invasive, more personalized treatments is addressing the most complex health challenges. Healthcare areas include: Cardiovascular, Orthopaedics, Surgery and Vision.
Innovating in healthcare
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.
Moving toward a more personalized approach to treating depression
The World Health Organization predicts that depression will be the leading cause of disability across the globe by 2030. Learn how Johnson & Johnson is on a mission to change that.
Juvenile myasthenia gravis: Inside one adolescent’s journey
The condition is typically diagnosed in adults, but research suggests an uptick in adolescent patients. Learn more about the rare autoantibody disease, how one teen is managing it and why Johnson & Johnson is working to improve treatment options for patients of all ages.
What you need to know about Johnson & Johnson’s 2025 third-quarter earnings
Here’s an infographic breakdown of the company’s third-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.
“Our goal is a solution for every bladder cancer patient”
Meet Christopher Cutie, M.D., the Johnson & Johnson scientist who’s helping change the treatment landscape for people with bladder cancer, the tenth most common cancer in the world.
Learn more about how we are innovating
Johnson & Johnson’s decades-long quest to develop effective treatments for IBD
Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.
“I helped create the lens that treated my mom’s cataracts”
Learn about one employee’s very personal mission to help restore vision for people who undergo cataract surgery.
Inside the development of a revolutionary treatment for blood cancers
In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
Meet two Johnson & Johnson nurse educators dedicated to teaching cancer care providers
Jennifer Huff and Jacqui Mellott are two of Johnson & Johnson’s oncology clinical educators—a team of 50 nurses who visit hospitals and infusion centers to help providers understand and stay up to date with treatments.